Long
TermOutcomesofPomalidomideandDexamethasoneinPatients
WithRelapsedMultipleMyeloma:Analysis4YearsAftertheOriginalCohort
JosephR.Mikhael,MD1SuzanneR.Hayman,MD2KristinaLaumann2VivekRoy,MD3BetsyLaPlantMS2ShajiKumar,MD2FrancisBuadi,MD2CraigReeder,MD1
MorieA.Gertz,MD2AngelaDispenzieri,MD2JohnA.Lust,MD,PhD2A.KeithStewart,MD1StephenJRussel ,MD,PhD2P.LeifBergsagel,MD1DavidDingli,MD2
StevenZeldenrust,MD2RafaelFonseca,MD1PhilipR.Greipp,MD2RobertHal ,RN,CNP2S.VincentRajkumar,MD2MarthaQ.Lacy,MD2
MayoClinic1Scottsdale,Arizona2Rochester,Minnesota3Jacksonville,Florida
Background
Results
Response
immunomodulatory(IMiD)drugwithhigh
Figure1:
Figure3:
fromNovember2007toAugust2008
responseratesinrelapsedmultiplemyeloma
KaplanMeierPFSWholeCohort
SurvivalbyPriorIMiDUse
(1
47)
(MM),includingthosepreviouslytreated
withthalidomide,bortezomib,and
With median follow
up of 33.6 months,
lenalidomide
overall response was seen in 39 (65%)
sCR
4 (7%)
(msmart.org)
CR
4 (7%)
outcomeisunknown
VGPR
15 (25%)
PR
16 (27%)
patientstreatedwithPomalidomidefromthe
PriorTherapies
withhigh
riskdisease
Methods
Patientswithrelapsed/refractorymyeloma
with1
3priortherapieswereenrolled
Pomalidomide2mg/dwasgivenorally
Toxicities
Progression
free survival (PFS):
continuouslyon28daycyclewithweekly
13 months (Figure 1)
dexamethasone40mg
Figure2:
Conclusions
toPomalidomide:
6 months
73%
AllpatientsreceivedDVTprophylaxiswith
12 months
73%
aspirin,heparin,orwarfarin
Grade3 Grade4
Overall survival (OS) not reached
effectiveandwell
toleratedinrelapsedMM
12 months
91%
24 months
76%
withmultiplepriortherapies,includingother
OutcomesinSelectedGroups
IMiDs,bortezomib,andtransplant
Grade3 Grade4
adurableresponsewithmedianduration
over21months
OSnotreached